Pregnancy: There is no indication for use of FOLISAN (r-hFSH) during pregnancy. No teratogenic risk has been reported, following controlled ovarian hyper stimulation, in clinical use with gonadotrophins. However to date, no particular malformative effect has been reported.
In case of exposure during pregnancy, clinical data are not sufficient to exclude a teratogenic effect of FOLISAN (r-hFSH).
Breastfeeding: FOLISAN (r-hFSH) is not indicated during breastfeeding. During lactation, the secretion of prolactin can result in a poor prognosis of ovarian stimulation.